EDAP TMS S.A. Reports Record Revenue in 2023
Ticker: EDAP · Form: 6-K · Filed: Jun 7, 2024 · CIK: 1041934
| Field | Detail |
|---|---|
| Company | Edap Tms SA (EDAP) |
| Form Type | 6-K |
| Filed Date | Jun 7, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: revenue, financial-report, foreign-issuer
TL;DR
EDAP TMS SA hit record revenue in 2023, filing a 6-K on June 7th.
AI Summary
EDAP TMS S.A. reported a very productive and successful 2023, achieving record revenue and placing a record number of its devices. The company filed a Form 6-K on June 7, 2024, to report on its activities, with Ken Mobeck, Chief Financial Officer, signing the document on June 7, 2024.
Why It Matters
This filing indicates strong financial performance for EDAP TMS S.A. in the past year, potentially signaling positive future growth and market position.
Risk Assessment
Risk Level: low — The filing is a routine report of foreign private issuer and does not contain significant new financial or operational risks.
Key Numbers
- record revenue — Revenue (Achieved in 2023)
- record number — Device Placements (Achieved in 2023)
Key Players & Entities
- EDAP TMS S.A. (company) — Registrant
- Ken Mobeck (person) — Chief Financial Officer
- 2023 (date) — Reporting year
- June 7, 2024 (date) — Filing date
FAQ
What specific financial figures constitute the 'record revenue' for 2023?
The filing does not provide specific dollar amounts for the record revenue achieved in 2023; it is stated qualitatively.
What type of devices did EDAP TMS S.A. place a record number of?
The filing mentions a 'record number' of its devices were placed but does not specify the type of devices.
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Who signed the Form 6-K on behalf of EDAP TMS S.A.?
Ken Mobeck, Chief Financial Officer, signed the report on behalf of EDAP TMS S.A.
When was the Form 6-K filed with the SEC?
The Form 6-K was filed with the SEC on June 7, 2024.
Filing Stats: 4,767 words · 19 min read · ~16 pages · Grade level 13.8 · Accepted 2024-06-07 16:36:03
Filing Documents
- f6k_060524.htm (6-K) — 444KB
- edap.jpg (GRAPHIC) — 2KB
- 0001171843-24-003343.txt ( ) — 448KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: June 7, 2024 EDAP TMS S.A. /s/ KEN MOBECK KEN MOBECK CHIEF FINANCIAL OFFICER June 4 th , 2024 Dear Fellow Shareholders: Looking back, 2023 proved to be a very productive and successful year for our company. We achieved both record revenue and placed a record number of Focal One systems, establishing robotic HIFU as a fast growing treatment modality for the management of prostate cancer. We also experienced strong Focal One procedure growth, which reflects increasing adoption of robotic HIFU technology, as well as our growing installed base of Focal One systems. In parallel with our commercial success, we also achieved significant clinical and regulatory milestones throughout the year. In December, we announced a positive opinion for reimbursement from the French National Authority for Health (HAS) for the treatment of localized prostate cancer with HIFU technology. In July, we announced reimbursement approval in Switzerland for the use of HIFU in the treatment of prostate cancer, enabling Swiss patients to have greater access to a precise and effective treatment option with the potential of fewer side effects. Earlier in 2023, we announced the approval of our ExactVu micro-ultrasound biopsy platform in Japan, which represents the second largest market for advanced medical device technology in the world. We also made significant progress in our clinical pipeline in 2023, highlighted by the progress on our Phase 2 and Phase 3 clinical trials evaluating Focal One robotic HIFU technology to treat women with deep infiltrating endometriosis. Of particular note, FDA recently granted Breakthrough Device designation for Focal One for the treatment of deep infiltrating endometriosis, which speaks to the importance of developing new treatment approaches for addressing thi